Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Elexacaftor→

Elexacaftor Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2216712-66-0
Molecular formula
C26H34F3N7O4S
Molecular weight
597.7 g/mol
Drug class
CFTR correctorcomponent of elexacaftor/tezacaftor/ivacaftor combination
Mechanism of action
Binds CFTR at a distinct site from tezacaftor and improves folding, processing and trafficking of F508del-mutant CFTR to the cell surface. It is used with tezacaftor and ivacaftor, which further correct CFTR processing and potentiate channel opening.
Indications / reported uses
  • Component of the fixed triple combination TRIKAFTA/KAFTRIO for treatment of cystic fibrosis in eligible patients with at least one responsive CFTR mutation; not a standalone approved indication

Sources: US DailyMed — TRIKAFTA · EMA EPAR — Kaftrio · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Elexacaftor Environmental Risk Assessment (ERA) (the Elexacaftor ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.